Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455519 | 0.83 | KDM4E (0.47) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL564237 | 0.80 | KDM4E (0.44) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL564769 | 0.80 | LMNA (0.46) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL3844688 | 0.80 | KDM4E (0.44) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL8571925 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL6518079 | 0.79 | KDM4E (0.47) | ALDH1A1KDM4ELMNAGAAPOLB | |
| Hydrochloric Acid SCHEMBL4504877 | 0.79 | KDM4E (0.43) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL21787707 | 0.79 | KDM4E (0.43) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL2851573 | 0.78 | NCF1 (0.37) | ALDH1A1KDM4ELMNAGAAHPGD | |
| SCHEMBL862762 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | claimed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | claimed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | claimed |
| CN-101679247-A | Process for preparing non-steroidal anti-inflammatory drugs and intermediates thereof | INTENDIS GMBH | 2010-03-24 | — | — | CN | claimed |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-11-06 | — | — | US | claimed |
| EP-1982976-A1 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | Intendis GmbH (DE) | 2008-10-22 | — | — | EP | claimed |
| WO-2020012865-A1 | QUINOPHTHALONE COMPOUND | DIC株式会社 | 2020-01-16 | — | — | WO | disclosed |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| CN-101679247-B | Process for preparing non-steroidal anti-inflammatory drugs and intermediates thereof | INTENDIS GMBH | 2014-02-19 | — | — | CN | disclosed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | ALDH1A1 760/4885KDM4E 3270/4885LMNA 3196/4885 |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | ALDH1A1 1684/4885KDM4E 1779/4885LMNA 3079/4885 |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | ALDH1A1 1684/4885KDM4E 1779/4885LMNA 3079/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ALDH1A1 1538/4885KDM4E 3072/4885LMNA 3290/4885 |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | CYP2F1, CYP4A11, CYP11B1 | ALDH1A1 1720/4885KDM4E 1742/4885LMNA 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.